Guidelines for the treatment of insomia standards of the Polish Sleep Research Society;Standardy leczenia bezsenności Polskiego Towarzystwa Badań nad Snem

Sen

Volumn 6, Issue SUPPL. A, 2006, Pages

  Szelenberger, Waldemar ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Antidepressants; Hypnotics; Insomnia; Nonpharmacological treatment for primary insomia

Indexed keywords

AFOBAM; ALPRAZOLAM; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORDIAZEPOXIDE; CLONAZEPAM; CLONAZEPAMUM; CLORANXEN; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; DIAZEPAM; ESZOPICLONE; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC AGENT; LORACARBEF; LORAZEPAM; MIDAZOLAM; MIDAZOLAM MALEATE; NITRAZEPAM; NOCTOFER; OXAZEPAM; PENTOBARBITAL; RAMELTEON; SELOFEN; SIGNOFAM; TEMAZEPAM; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

DEPRESSION; DRUG RECEPTOR BINDING; HUMAN; INSOMNIA; MEDICAL SOCIETY; MEMORY DISORDER; PALLIATIVE THERAPY; POLAND; PSYCHOMOTOR DISORDER; PUBLIC HEALTH PROBLEM; REVIEW;

EID: 33846405635     PISSN: 16416007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Miedzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych, rewizja dziesiata. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Opisy kliniczne i wskazówki diagnostyczne. Uniwersyteckie Wydawnictwo Medyczne "Vesalius", Instytut Psychiatrii i Neurologii, Kraków-Warszawa 2000.
2. Costa e Silva J.A., Chase M., Sartorius N., Roth T. Special Report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: An overview of insomnias and related disorders - recognition, epidemiology, and rational management. Sleep 1996; 19: 412-416.
3. Szelenberger W., Skalski M. Epidemiologia zaburzeń snu w Polsce. Doniesienie wstepne. W: Nowicki Z., Szelenberger W. red. Zaburzenia snu. Diagnostyka i leczenie. Wybrane zagadnienia. Biblioteka Psychiatrii Polskiej, Kraków 1999; 57-63.
4. Ancoli-Israel S., Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999; 22 (supl. 2): S347-S353.
5. Bixler E.O., Vgontzaa A.N., Lin H.M., Vela-Bueno A., Kales A. Insomnia in central Pennsylvania. J. Psychosom. Res. 2002; 53: 589-592.
6. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbance and psychiatric disorders: An opportunity for prevention? JAMA 1989; 262: 1479-1484.
7. Kales A., Kales J.D. Evaluation and Treatment of Insomnia. Oxford University Press, New York 1984.
8. Katz D.A., McHorney C.A. Clinical correlates of insomnia in patients with chronic illness. Arch. Intern. Med. 1998; 158: 1099-1107.
9. Wingard D.L., Berkman L.F. Mortality risk associated with sleeping patterns among adults. Sleep 1983; 6: 102-107.
10. Ohayon M. Epidemiological study on insomnia in the general population. Sleep 1996; 19 (supl.): S7-S15.
11. Ohayon M.M., Roth T. Place of chronic insomnia hi the course of depressive and anxiety disorders. J. Psychiatr. Des. 2003; 37: 9-15.
12. Ohayon M.M., Caulet M., Lemoine P. Comorbidity of mental and insomnia disorders in the general population. Compr. Psychiatry 1998; 39: 185-197.
13. Soldatos C.R. Insomnia in relation to depression and anxiety epidemiologic considerations. J. Psychosom. Res. 1994; 38 (supl. 1): 3-8.
14. Tan T.L., Kales J.D., Kales A., Soldatos C.R., Bixler E.O. Biopsychobehavioral correlates of insomnia. IV. Diagnosis based on DSM-III. Am. J. Psychiatry 1984; 141: 357-362.
15. National Institute of Mental Health. Consensus Development Conference: Drugs and insomnia. The use of medications to promote sleep. JAMA 1984; 251: 2410-2414.
16. Mellinger G.D., Balter M.B., Uhlenhuth E.H. Insomnia and its treatment. prevalence and correlates. Arch. Gen. Psychiatry 1985; 42: 225-232.
17. Perlis M.L., Giles D.E., Buysse D.J., Tu X., Kupfer D.J. Self-reported sleep disturbances as a prodromal symptom in recurrent depression. J. Affect. Disord. 1997; 42: 209-212.
18. Coleman R.M., Roffwarg H.P., Kennedy S.J. i wsp. Sleep-wake disorders based on polysomnographic diagnosis. A national cooperative study. JAMA 1982; 247: 997-1003.
19. Buysse D.J., Reynolds C.F., Kupfer D.J. i wsp. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 categories: A report from the APA/ NIMH DSM-IV Field Trial. Sleep 1994; 17: 630-637.
20. Skalski M., Szelenberger W. The frequency of DSM-IV disorders diagnoses in Warsaw Sleep Disorders Clinic. J. Sleep Res. 2000; 9 (supl. 1): 176.
21. Nowell P.D., Buysse D.J., Reynolds C.F. i wsp. Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Am. J. Psychiatry 1997; 154: 1412-1416.
22. Szelenberger W., Niemcewicz S., Skalski M. Bezsenność: aktualny stan wiedzy. W: Szelenberger W. red. Bezsenność. Fundacja Wspierania Rozwoju Kliniki Psychiatrycznej Akademii Medycznej w Warszawie, Warszawa 2000; 7-64.
23. Benca R.M. Mood disorders. W: Kryger M.D., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 1140-1157.
24. Vgontzas A.N., Tsigos C., Bixler E.O. i wsp. Chronic insomnia and activity of the stress system: A preliminary study. J. Psychosom. Res. 1998; 45: 21-31.
25. Vgontzas A.N., Bixler E.O., Lin H.M. i wsp. Chronic insomnia is associated with nyctohemeral activation of hypothalamic-pituitary-adrenal axis: clinical implications. J. Clin. Endocrinol. Metab. 2001; 86: 3787-3794.
26. Breslau N., Roth T., Rosenthal L., Andreski P. Sleep disturbances and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol. Psychiatry 1996; 39: 411-418.
27. Chang P.P., Ford D.E., Mead L.A., Cooper-Patrick L., Klag M.J. Insomnia in young men and subsequent depression. The Johns Hopkins precursor study. Am. J. Epidemiol. 1997; 146: 105-114.
28. Eaton W.W., Badawi M., Melton B. Prodromes and precursors: epidemiologic data for primary prevention of disorder with slow onset. Am. J. Psychiatry 1995; 152: 967-972.
29. Vgontzas A.N., Bixler E.O., Vela-Bueno A., Kales A. Insomnia: does it exist independently of psychopathology? How similar or different is its pathophysiology from the underlying mental disorder? J. Sleep Res. 1998b; 7 (supl. 2): 293.
30. Vgontzas AN. The diagnosis and treatment of chronic insomnia in adults. Sleep 2005; 28: 1047-1048.
31. Richardson G.S., Roth T. Future directions in the management of insomnia. J. Clin. Psychiatry 2001; 62 (supl. 10): 39-45.
32. Ashton H. Guidelines for the rational use of benzodiazephses. Drugs 1994; 48: 25-40.
33. Arendt J., Czeisler C., Dawson D. i wsp. In what circumstances is melatonin a useful sleep therapy? Consensus statement, WFSRS Focus Group, Dresden, November 1999. J. Sleep Des. 2000; 9: 397-398.
34. Langer S., Mendelson W., Richardson G. Symptomatic treatment of insomnia. Sleep 1999; 22 (supl. 3): S437-S450.
35. Roth T., Hajak G., Ustun TB. Consensus for the pharmacological management of insomnia in the new millennium. Int. J. Clin. Pract. 2001; 55: 42-52.
36. Erman M.K. Therapeutic options in the treatment of insomnia. J. Clin. Psychiatry 2005; 66 (supl. 9): 18-23.
37. Zee P.C. Sleep promoting role of melatonin receptor agonists. Sleep 2005; 28: 300-301.
38. Griffiths R.R., Johnson M.W. Relative abuse reliability of hypnotic drugs: A conceptual framework and algorithm for differnitating among compounds. J. Clin. Psychiatry 2005; 66 (supl.): 31-41.
39. Roth T., Stubbs C., Walsh J.K. Ramelteon (TK-375), a selective MT1/MT2 - receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28: 303-307.
40. Mendelson W.B. Hypnotics: Basic mechanisms and pharmacology. W: Kryger M.H., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 407-413.
41. Bezchlibnyk-Butler K., Jeffries J.J. Clinical Handbook of Psychotropic Drugs, wydanie IX. Hogrefe & Huber Publishers, Seattle 1999.
42. Bonnet M.H., Arand DL. 24-hour metabolic rate in insomniacs and matched normal sleepers. Sleep 1995; 18: 581-588.
43. Bonnet M.H., Arand D.L. Physiological activation in patients with sleep state misperception. Psychosom. Med. 1997; 59: 533-540.
44. Bonnet M.H., Arand D.L. The use of lorazepam TID for chronic insomnia. Int. Clin. Psychopharmacol. 1999; 14: 81-89.
45. Freedman R.R., Sattler H. Physiological and psychological factors in sleep onset insomnia. J. Abnorm. Psychol. 1982; 91: 380-389.
46. Perlis M.L., Giles D.E., Mendelson W.B., Bootzin R.R. Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. J. Sleep Des. 1997; 6: 179-188.
47. Greenblatt D.J. Pharmacology of benzodiazepine hypnotics. J. Clin. Psychiatry 1992; 53 (supl. 6): 7-13.
48. Hishikawa Y. Appropriate use of benzodiazepines in insomnia: Clinical update. J. Clin. Psychiatry 1991; 52 (supl. 7): 10-13.
49. Castleden C.M., George C.F., Marcer D., Hallett C. Increased sensitivity to nitrazepam in old age. Br. Med. J. 1977; 1: 10-12.
50. Mendelson W.B., Thompson C., Franko T. Adverse reactions to sedative/ hypnotics: three years' experience. Sleep 1996; 19: 702-706.
51. Bixler E.O., Kales A., Manfredi R.L., Vgontzas A., Tyson K.L., Kales J.D. Next-day memory impairment with triazolam use. Lancet 1991; 337: 827-831.
52. Kales A., Soldatos C.R., Bixler E.O., Kales J.D. Rebound insomnia and rebound anxiety: a review. Pharmacology 1983a: 26: 121-137.
53. Kales A., Soldatos C.R., Bixler E.O., Goff P.J., Vela-Bueno A. Midazolam: dose-response studies of effectiveness and rebound insomnia. Pharmacology 1983b; 26: 138-149.
54. Roehrs T., Vogel G., Roth T. Rebound insomnia: its determinants and significance. Am. J. Med. 1990; 88: 39S-42S.
55. Scharf M.B., Fletcher K., Graham J.P. Comparative amnestic effects of benzodiazepine hypnotic agents. J. Clin. Psychiatry 1988; 49: 134-137.
56. Hutchinson M.A., Smith P.F., Darlington C.L. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Progr. Neurobiol. 1996; 49: 73-97.
57. Adam K., Adamson L., Brezinova V., Hunter W., Oswald I. Nitrazepam: lastingly effective but trouble on withdrawal. Br. Med. J. 1976; 1: 1558-1560.
58. Jovanovic U.J., Dreyfus J.F. Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. Pharmacology 1983; 27 (supl. 2): 136-145.
59. Walsh J.K., Vogel G.W., Scharf M. i wsp. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med. 2000; 1: 41-49.
60. Roth T., Walsh J.K., Krystal A., Wessel T., Roehrs T.A. An evalution of the efficacy and safety of eszopiklone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005; 6: 487-495.
61. Kales A., Scharf M.B., Kales J.D. Rebound insomnia: a new clinical syndrome. Science 1978; 201: 1039-1041.
62. Kales A., Scharf M.B., Kales J.D., Soldatos C.R. Rebound insomnia: a potential hazard following withdrawal of certain benzodiazepines. JAMA 1979; 241: 1692-1695.
63. Bliwise B., Seidel W., Greenblatt D.J., Dement W. Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. Am. J. Psychiatry 1984; 141: 191-195.
64. Kales A., Allen C., Scharf M.B., Kales J.D. Hypnotic drugs and their effectiveness: all-night EEG studies of insomniac subjects. Arch. Gen. Psychiatry 1970a; 23: 226-232.
65. Kales A., Kales J.D., Scharf M.B., Tan T.L. Hypnotics and altered sleep-dream patterns. II. All-night EEG studies of chloral hydrate, flurazepam, and methaqualone. Arch. Gen. Psychiatry 1970b; 23: 219-225.
66. Lobo B.L., Greene W.L. Zolpidem: distinct from triazolam? Ann. Pharmacother. 1997; 31; 625-632.
67. Sperling R., Greve D., Dale A. i wsp. Functional MRI detection of pharmacologically induced memory impairment. Proc. Natl. Acad. Sci. 2002; 99: 455-460.
68. O'Hanlon J.F. Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. Primary Care Companion J. Clin. Psychiatry 2002; 4 (supl. 1): 38-44.
69. Pomara N., Deptula D., Medel M., Block R.J., Greenblatt D.J. Effects of diazepam on recall memory: relationship to aging, dose, and duration of treatment. Psychopharmacol. Bull. 1989; 25: 144-148.
70. Hindmarch I., Ott H. Sleep, benzodiazepines and performance: Issues and comments. W: Hindmarch I., Ott H., Roth T. red. Sleep, Benzodiazepines and Performance. Experimental Methodologies and Research Prospects. Springer-Verlag, Berlin 1984; 194-202.
71. Paterniti S., Dufouil C., Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J. Clin. Psychopharmacol. 2002; 22: 285-293.
72. Hajak G., Cluydts R., Declerck A., Estivill SE., Middleton A., Sonka K. i wsp. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int. Clin. Psychopharmacol. 2002a; 17: 9-17.
73. Lader M. Anxiety or depression during withdrawal of hypnotic treatments. J. Psychosom. Res. 1994; 38 (supl.): 113-123.
74. Lader M.H. Managing dependence and withdrawal with newer hypnotic medications in the treatment of insomnia. Primary Care Companion J. Clin. Psychiatry 2002; 4 (supl. 1): 33-37.
75. Shiloh R., Nutt D., Weizman A. Essentials in Clinical Pharmacotherapy. Martin Dunitz Ltd., London 2001.
76. Schweitzer E., Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr. Scand. 1998; 98 (supl. 393): 95-101.
77. Gillin J.C., Drummond S.P.A. Medication and substance abuse. W: Kryger M.H., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 1176-1195.
78. Shapiro C.M., MacFarlane J.G., MacLean A.W. Alleviating sleep-re]ated discontinuance symptoms associated with benzodiazepine withdrawal: anew approach. J. Psychosom. Des. 1993; 37 (supl. 1): 55-57.
79. Bootzin R., Epstein D., Wood J.M. Stimulus control instructions. W: Hauri P.J. red. Case Studies in Insomnia. Plenum Medical Book Co., New York 1991; 19-28.
80. Benoit O., Aguirre A. Homeostatic and circadian aspects of sleep regulation in young poor sleepers. Neurophysiol. Clin. 1996; 26: 40-50.
81. Besset A., Villemin E., Tafti M., Billiard M. Homeostatic process and sleep spindles in patients with sleep-maintenance insomnia: effect of partial (21 h) sleep deprivation. Electroencephalogr. Clin. Neurophysiol. 1998; 107: 122-132.
82. Glovinsky P.B., Spielman A.J. Sleep restriction therapy. W: Hauri P.J. red. Case Studies in Insomnia. Plenum Medical Book Co., New York 1991; 49-63.
83. Spielman A.J., Saskin P., Thorpy M.J. Treatment of chronic insomnia by restriction of time in bed. Sleep 1987; 10: 45-56.
84. Hajak G., Bandelow B., Zulley J., Pittrow D. "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia - assessment of a novel intervention strategy in a primary care setting. Ann. Clin. Psychiatry 2002b; 14: 1-7.
85. Hauri P.J. Psychological and psychiatric issues in the etiopathogenesis of insomnia. Primary Care Companion J. Clin. Psychiatry 2002; 4 (supl. 1): 17-20.
86. Morin C.M. Contributions of cognitive-behavioral approaches to the clinical management of insomnia. Primary Care Companion J. Clin. Psychiatry 2002; 4 (supl. 1): 21-26.
87. Wagstaff A.N., Ormrod D., Spencer C.M. Tianeptine. A review of its use in depressive disorders. CNS Drugs 2001; 15: 231-259.
88. Hajak G., Rodenbeck A., Voderholzer U. i wsp. Doxepin in the treatment of primary insomnia - a placebo-controlled, double-blind, polysomnographic study. J. Clin. Psychiatry 2001; 62: 453-463.
89. Riemann D., Voderholzer U., Cohrs S. i wsp. Trimipramine in primary insomnia: Results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002; 35: 165-174.
90. Walsh J.K., Schweitzer P.K. Ten-years trends in the pharmacological treatment of insomnia. Sleep 1999; 22: 371-372.
91. Gillin J.C., Rapaport M., Erman M.K., Winokur A., Albala B.J. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J. Clin. Psychiatry 1997; 58: 185-192.
92. Hendrickse W.A., Roffwarg H.P., Grannemann B.D. i wsp. The effects of fluoxetine on the polysomnogram of depressed outpatients: A pilot study. Neuropsychopharmocology 1994; 10: 85-91.
93. Luthringer R., Toussaint M., Schaltenbrand N. i wsp. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol. Bull. 1996; 32: 637-646.
94. Rush A.J., Armitage R., Gillin J.C. i wsp. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol. Psychiatry 1998; 44: 3-14.
95. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. J. Clin. Paychiatry 1999; 60 (supl. 17): 28-31.
96. Schweitzer P.K. Drugs that disturb sleep and wakefulness. W: Kryger M.H., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 441-461.
97. Roth B., Nevsimalova S. Depression in narcolepsy and hypersomnia. Schweiz. Arch. Neurol. Psychiatr. 1975; 116: 291-300.
98. Montplaisir J., Nicolas A., Godbout R., Walters A. Restless legs syndrome and periodic limb movement disorder. W: Kryger M.H., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 742-752.
99. Mahowald M.W., Schenck C.H. REM sleep parasomnias. W: Kryger M.H., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 724-741.
100. Bliwise D.L. Dementia. W: Kryger M.D., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. III. W.B. Saunders Co., Philadelphia 2000; 1058-1071.
101. Garcia-Borreguero D., Larrosa O., de la Llave Y., Verger K., Masramon X., Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59: 1573-1579.
102. Sammaritano M.R., Sherwin A.L. Effect of anticonvulsants on sleep. W: Bazil C.W., Malow B.A., Sammaritano M.R. red. Sleep and Epilepsy: The Clinical Spectrum. Elsevier Science B.V., Amsterdam 2002; 187-194.
103. Nicholson A.N. Hypnotics: Clinical pharmacology and therapeutics. W: Kryger M.H., Roth T., Dement W.C. red. Principles and Practice of Sleep Medicine, wyd. II. W.B. Saunders Co., Philadelphia 1994; 355-363.